Abstract
Agents available or in development for the treatment of chronic hepatitis B virus (HBV) infection fall into two major groups: immunomodulators, such as interferon-α and therapeutic vaccines, and nucleoside/nucleotide analogs, such as lamivudine and adefovir (1). Currently, the only therapies approved in the United States for treatment of chronic HBV infection are IFN-α and lamivudine. However, a number of nucleoside and nucleotide analogs are in development, and it is likely that treatment of chronic HBV infection in the future will involve additional therapies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Yuen, M-F. and Lai, C-L. (2001) Treatment of chronic hepatitis B. Lancet Infect. Dis. 1, 232–241.
Lok, A. and McMahon, B. (2001) Chronic hepatitis B (review). Hematology 34, 1225–1241.
Nordstrom, T, Gharizadeh, B., Pourmand, N., Nyron, P., and Ronaghi, M. (2001) Method enabling fast partial sequencing of cDNA clones. Analyt. Biochem. 292, 266–271.
Taylor, J., Briley, D., Nguyen, Q., et al. (2001) Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. BioTechniques 30, 661–666, 668–669.
Hsu, T., Law, S., Duan, S., Neri, B., and Kwok, P. (2001) Genotyping single-nucleotide polymorphism by the invader assay with dual-color fluorescence polarization detction. Clin. Chem. 47, 1373–1377.
Allen, M., Gauthier, J., DesLauriers, M., et al. (1999) Two sensitive PCR-based methods for the detection of variants associated with reduced susceptibility to lamivudine. J. Clin. Microbiol. 37, 3338–3347.
Fallows, D. and Goff S. (1995) Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J. Virol. 69, 3067–3073.
Allen, M., DesLauriers, M., Andrews, C., et al. (1998) Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27, 1670–1677.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this protocol
Cite this protocol
Bourne, E.J., Gauthier, J., Lopez, V.A., Condreay, L.D. (2004). Genotyping Anti-Hepatitis B Virus Drug Resistance. In: Hamatake, R.K., Lau, J.Y.N. (eds) Hepatitis B and D Protocols. Methods in Molecular Medicine™, vol 96. Humana Press. https://doi.org/10.1385/1-59259-670-3:379
Download citation
DOI: https://doi.org/10.1385/1-59259-670-3:379
Publisher Name: Humana Press
Print ISBN: 978-1-58829-108-0
Online ISBN: 978-1-59259-670-6
eBook Packages: Springer Protocols